AIDS 2012: Syringe Exchange Expansion in U.S. Would be Cost-saving
- Details
- Category: HIV Prevention
- Published on Tuesday, 31 July 2012 00:00
- Written by Kelly Safreed-Harmon
According to a mathematical analysis presented at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, providing clean syringes to reduce HIV transmission among Americans who inject drugs is considerably less expensive than treating the new cases of HIV that would occur in the absence of this intervention.
AIDS 2012: Once-daily Elvitegravir Suppresses HIV as well as Raltegravir at 96 weeks
- Details
- Category: HIV Treatment
- Published on Monday, 30 July 2012 00:00
- Written by Liz Highleyman
The investigational HIV integrase inhibitor elvitegravir taken once-daily continued to perform as well as twice-daily raltegravir (Isentress) at 96 weeks for treatment-experienced people with extensive drug resistance, according to data presented last week at the 19th International AIDS Conference (AIDS 2012) in Washington, DC.
AIDS 2012: Berlin Patient Timothy Brown Launches Foundation for HIV Cure [VIDEO]
- Details
- Category: Search for a Cure
- Published on Monday, 30 July 2012 00:00
- Written by Gregory Fowler
Timothy Ray Brown -- better know as the "Berlin Patient," the first person known to be cured of HIV -- launched a new foundation to raise funds for HIV cure research at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. He took the opportunity to announce that he is still free of HIV. 
AIDS 2012: Cobicistat Matches Ritonavir as Booster for Atazanavir
- Details
- Category: HIV Treatment
- Published on Monday, 30 July 2012 00:00
- Written by Liz Highleyman
The novel boosting agent 
cobicistat works as well as ritonavir (Norvir) as a pharmacoenhancer, or booster, for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to a report presented last week at the 19th International AIDS Conference in Washington, DC.
AIDS 2012: Dolutegravir Matches Raltegravir for People Starting HIV Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 27 July 2012 00:00
- Written by Liz Highleyman
The novel integrase inhibitor dolutegravir worked as well as raltegravir (Isentress) at 48 weeks for treatment-naive people in the Phase 3 SPRING-2 study, according to a late-breaker presentation at the 19th International AIDS Conference (AIDS 2012) this week in Washington, DC.
Web Design and Development by